期刊
MOLECULAR IMMUNOLOGY
卷 46, 期 4, 页码 532-540出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.molimm.2008.07.023
关键词
Prions; Monoclonal antibody; Conformation specificity; Complementarity determining regions; Recombinant antibodies; Retro-inverso D-peptides
资金
- Forschungskommission of the University of Dusseldorf Medical School
- VW foundation
- TSE-Program Baden-Wuerttemberg [729.59-7/1]
- DFG [GRK1033]
- FP6
- EU Research Commission Anteprion [LSHB-C7-2006-019090]
The prion protein, PrP, exists in several stable conformations, with the presence of one conformation, PrPSc, associated with transmissible neurodegenerative diseases. Targeting PrP by high-affinity ligands has been proven to be an effective way of preventing peripheral prion infections. Here, we have generated bacterially expressed single chain fragments of the variable domains (scFv) of a monoclonal antibody in Escherichia coli, originally raised against purified PrPSc that recognizes both PrPc and PrPSc. This scFv fragment had a dissociation constant (K-D) with recombinant PrP of 2 nM and cleared prions in ScN2a cells at 4 nM, as demonstrated by a mouse prion bioassay. A peptide corresponding to the complementarity determining region 3 of the heavy chain (CDR3H) selectively bound PrPSc but had lost antiprion activity. However, synthesis and application of an improved peptide mimicking side chain topology of CDR3H while exhibiting increased protease resistance, a retro-inverso D-peptide of CDR3H, still bound PrPSc and reinstated antiprion activity. We conclude that (1) scFvW226 is so far the smallest polypeptide with bioassay confirmed antiprion activity, and (2) differential conformation specificity and bioactivity can be regulated by orchestrating the participation of different CDRs. (C) 2008 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据